Dr. Delphine Rea, has been awarded the prestigious 2025 Goldman Prize in recognition of her exceptional contributions to the field of CML. The iCMLf Goldman Prize is one of the highest honors in CML research and treatment, celebrating individuals whose dedication and achievements have profoundly shaped the management of the disease. A distinguished hematologist based at Hôpital Saint-Louis in Paris, France, Dr. Rea's groundbreaking work has significantly advanced both clinical practice and research, making a lasting impact on the lives of people with CML worldwide."​

"Great input in new approaches in CML including stop trials, dose reduction trials, trials of new drugs. Outstanding and bright professional, scientist and person."
— Dr. Ekaterina Chelysheva

Pioneering research in treatment-free remission and new approaches

Delphine Rea has been instrumental in pioneering studies on treatment-free remission in CML patients. Her involvement in landmark trials, such as the STIM and STOP 2G-TKI studies, has provided critical insights into the feasibility and safety of discontinuing tyrosine kinase inhibitors (TKIs) in patients who achieve deep molecular responses. These studies have helped redefine treatment goals, offering many patients the possibility of maintaining remission without continuous therapy. Her work has addressed challenging questions regarding when it is safe to stop TKI therapy in CML management. ​

Dr. Rea has also made significant contributions to the clinical optimization and development of targeted therapies. Her work in this field has helped establish asciminib, the first allosteric TKI against BCR::ABL1, as an effective option for patients with resistance or intolerance to previous TKI therapies. By contributing to the understanding of asciminib's efficacy and safety profile, Dr. Rea has played a crucial role in expanding treatment options for CML patients.

Leadership in understanding the impact on COVID-19 for patients with CML

During the COVID-19 pandemic, Dr Rea demonstrated exceptional leadership in understanding the impact of the coronavirus on CML patients. She played a central role in the iCMLf CANDID study, the largest global real-world collection, from 157 institutions in 49 countries, characterizing CML patients with COVID-19. 

Clinical excellence and scientific advancements

Delphine Rea's medical career is distinguished by her dedication to both patient care and scientific advancement. As a hospital practitioner at Hôpital Saint-Louis APHP, University Paris Cité, where she completed her specialization in hematology, she has become an expert in CML, actively contributing to the evolution of disease management and patient care over the past decade. Her extensive publication record, with over 370 peer-reviewed papers, underscores her commitment to advancing the understanding and treatment of CML. ​

Dr Delphine Rea's exemplary work embodies the spirit of the iCMLf Goldman Prize, reflecting her unwavering commitment to improving the lives of people living with CML worldwide.